Uncategorized

[CellChorus, Inc.] CellChorus, Inc. announced that the National Cancer Institute has awarded CellChorus® and Stanford Medicine a Phase I Small Business Innovation Research grant to profile cells from relapsed/refractory large B cell lymphoma patients after treatment with CAR-T cell therapy to develop a functional signature of response to therapy.

[Signal Transduction and Targeted Therapy] The emergence of in vivo CAR-T therapy medicinal products using viral vector or lipid nanoparticle platforms has provided a promising new direction by simplifying manufacturing, enhancing scalability, and lowering costs, though it may introduce elevated risks such as off-target effects and immunogenicity.

[Cancer Research] Through head-to-head in vivo comparisons of potentially synergistic armor combinations, researchers demonstrated that T cells expressing a CAR plus IL-12 and the decoy-resistant form of IL-18 show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice.

[Nature Medicine] CAR-expressing cells—initially developed and successfully used to treat certain cancers—are increasingly being developed to selectively deplete B cells and ‘reset’ the immune system in autoimmune diseases (AIDs).

[Nature Cancer] Using syngeneic models of extensive metastatic lung adenocarcinoma and melanoma, investigators showed that 8 Gy of tumor irradiation significantly enhanced CAR T cell persistence in a manner critically dependent on dendritic cells.

[Biomarker Research] The authors discuss the limitations of CAR-T and strategies to overcome them, specifically in the context of B cell acute lymphoblastic leukemia, including the use of allogeneic CAR-T, dual-targeted CAR-T, and combination strategies with novel technologies and agents.

[Trends in Biotechnology] This review synthesizes recent advances in CAR-T cell bioengineering aimed at overcoming physical barriers, immunosuppressive signaling, metabolic stress, and cellular exhaustion that characterize solid tumors, which are a leading cause of cancer-related mortality worldwide.

[Molecular Therapy] Researchers engineered iPSC-derived cytotoxic T cells transduced with a CAR and identified an optimal cytokine armoring strategy. Co-expression of interleukin (IL)-15 and IL-21 synergistically enhanceds STAT1 phosphorylation, leading to increased transcriptional activation of the chemokine receptor CXCR3.

[Science Translational Medicine] Scientists generated urokinase plasminogen activator receptor (uPAR)-specific CAR T cells, which demonstrated potent antitumor activity in recurrent glioblastoma patient–derived xenograft models.

[Molecular Therapy] Scientists monitored anti-CAR therapeutic domain-specific antibodies (ATAs) in 157 treated patients to assess treatment-related immunogenicity. The ATA status did not affect CAR T-cell expansion or patient survival outcomes, though reduced persistence was observed in ATA-positive patients.

[Scientific Reports] Researchers evaluated the impact of unmodified and RGD-functionalized GMP-grade alginate matrices on umbilical cord-derived MSCs viability, mitochondrial function, and cytokine secretion profile.

[Scientific Reports] Scientists investigated the effect of AMD3100 on culture expanded human bone marrow derived MSCs which are non-hematopoietic cells of the marrow niche. AMD3100 does not modulate the metabolic activity of bone marrow MSCs.